

Supplementary Table SI. Inclusion criteria

Inclusion criteria
Signed written informed consent.
Age \geq 18 years or legal age of majority at screening visit.
One of below and not adequately controlled with a maximally tolerated dose of statin* with or without other LLT, all at stable doses for at least 4 weeks prior to the screening visit (Week -3).
A. Patients with HeFH [†] with LDL-C concentrations \geq 160 mg/dl (4.14 mmol/l) despite treatment
B. Patients with HeFH with LDL-C concentrations \geq 130 mg/dl (3.36 mmol/l) despite treatment and two or more CV risk factors among this list: <ul style="list-style-type: none"> • LDL-C $>$ 250 mg/dl (6.46 mmol/l) at the time of the FH diagnosis (before treatment). • Family history of premature-onset CHD (first-degree male relative with onset before age 55 years; first-degree female relative with onset before age 65 years). • Metabolic syndrome[‡]. • HDL-C $<$ 40 mg/dl (1.03 mmol/l). • Hypertension (blood pressure $>$ 140/90 mm Hg or drug treatment). • Lp(a) \geq 50 mg/dl (1.78 μmol/l). • Tendon xanthoma.
C. Patients with HeFH with LDL-C \geq 130 mg/dl (3.36 mmol/l) despite treatment and one of the following characteristics: <ul style="list-style-type: none"> • Established CHD or other CVD (history of acute myocardial infarction, ischemic stroke, peripheral arterial disease, coronary or peripheral arterial revascularization, stable or unstable angina, transient ischemic attack, carotid artery stenosis \geq 50%, aortic abdominal aneurysm). • Drug-treated type 2 diabetes mellitus or type 1 with target organ damage. • Family history of first- or second-degree relative with very premature onset CHD (first- or second-degree male relative onset before age 45; first- or second-degree female relative onset before age 55).
D. Non-FH patients with established CHD or other CVD (history of acute myocardial infarction, ischemic stroke, peripheral arterial disease, coronary or peripheral arterial revascularization, stable or unstable angina, transient ischemic attack, carotid artery stenosis \geq 50%, aortic abdominal aneurysm) and with LDL-C \geq 130 mg/dl (3.36 mmol/l).
E. Patients with progressive CVD (coronary artery disease, or peripheral arterial occlusive disease or cerebrovascular disease as documented clinically or by imaging techniques, with a subsequent CV event (acute myocardial infarction, ischemic stroke, ischemia-driven revascularization, unstable angina, transient ischemic attack) occurring despite stable doses of maximally tolerated LLT) with LDL-C \geq 100 mg/dl (2.59 mmol/l).

*Maximally tolerated dose statin was defined as rosuvastatin 20 mg or 40 mg daily, atorvastatin 40 mg or 80 mg daily, or simvastatin 80 mg daily (if already on this dose for $>$ 1 year). Patients not able to be on any of the above statin doses should be treated with the dose of daily atorvastatin, rosuvastatin, or simvastatin which is considered appropriate for the patient as per the investigator's judgment or concerns. In exceptional and well-documented cases described in the exclusion criteria, another statin regimen may be used. [†]Diagnosis of HeFH was documented, either by genotyping or by clinical criteria. For patients who were not genotyped, the clinical diagnosis was based on either the Simon Broome criteria or the WHO/Dutch Lipid Network criteria and the diagnostic had to be "definite" (see Simon Broome criteria for "definite" or a diagnostic scoring $>$ 8 for WHO criteria). [‡]Metabolic syndrome was diagnosed by the presence of three of the following five characteristics: increased waist circumference (men $>$ 40 inches ($>$ 37 inches in some populations) and women $>$ 35 inches); blood pressure \geq 130 mm Hg or \geq 80 mm Hg or drug treatment; triglycerides \geq 150 mg/dl or drug treatment; low HDL-C (men $<$ 40 mg/dl and women $<$ 50 mg/dl); or elevated glucose (\geq 100 mg/dl) or drug treatment. CHD – coronary heart disease, CV – cardiovascular, CVD – cardiovascular disease, FH – familial hypercholesterolemia, HDL-C – high-density lipoprotein cholesterol, HeFH – heterozygous familial hypercholesterolemia, LDL-C – low-density lipoprotein cholesterol, LLT – lipid-lowering therapy, Lp(a) – lipoprotein(a), WHO – World Health Organization.

Supplementary Table SII. TEAEs by primary system organ class and preferred term according to background statin therapy* (safety population)

Primary System Organ Class Preferred term, n (%) of patients	High-intensity statin (n = 580)	Low/moderate-inten- sity statin (n = 181)	No statin (n = 233)
Any class	378 (65.2)	136 (75.1)	198 (85.0)
Infections and infestations:	160 (27.6)	50 (27.6)	93 (39.9)
Nasopharyngitis	39 (6.7)	14 (7.7)	25 (10.7)
Influenza	29 (5.0)	6 (3.3)	18 (7.7)
Bronchitis	21 (3.6)	6 (3.3)	18 (7.7)
Urinary tract infection	13 (2.2)	6(3.3)	8 (3.4)
Rhinitis	11 (1.9)	1 (0.6)	8 (3.4)
Gastroenteritis	10 (1.7)	2 (1.1)	8 (3.4)
Sinusitis	9 (1.6)	5 (2.8)	3 (1.3)
Upper respiratory tract infection	8 (1.4)	1 (0.6)	2 (0.9)
Tonsillitis	6 (1.0)	1 (0.6)	1 (0.4)
Viral infection	5 (0.9)	0	2 (0.9)
Cystitis	4 (0.7)	4 (2.2)	4 (1.7)
Diverticulitis	4 (0.7)	0	0
Pharyngitis	4 (0.7)	2 (1.1)	4 (1.7)
Pneumonia	4 (0.7)	2 (1.1)	2 (0.9)
Laryngitis	3 (0.5)	0	1 (0.4)
Oral herpes	3 (0.5)	2 (1.1)	1 (0.4)
Respiratory tract infection	3 (0.5)	0	2 (0.9)
Tooth abscess	3 (0.5)	1 (0.6)	3 (1.3)
Tooth infection	3 (0.5)	0	1 (0.4)
Cellulitis	2 (0.3)	0	1 (0.4)
Periodontitis	2 (0.3)	0	0
Viral pharyngitis	2 (0.3)	0	0
Bronchitis viral	1 (0.2)	0	0
Campylobacter colitis	1 (0.2)	0	0
Conjunctivitis	1 (0.2)	1 (0.6)	0
Ear infection	1 (0.2)	1 (0.6)	0
Escherichia sepsis	1 (0.2)	0	0
Fungal skin infection	1 (0.2)	0	0
Gastroenteritis viral	1 (0.2)	1 (0.6)	2 (0.9)
Gastrointestinal infection	1 (0.2)	0	0
Genital infection female	1 (0.2)	0	0
Gingivitis	1 (0.2)	1 (0.6)	0
Helicobacter gastritis	1 (0.2)	0	0
Helicobacter infection	1 (0.2)	0	1 (0.4)
Herpes virus infection	1 (0.2)	1 (0.6)	0
Herpes zoster	1 (0.2)	0	3 (1.3)
Hordeolum	1 (0.2)	0	0
Nail bed infection	1 (0.2)	0	0
Otitis media	1 (0.2)	1 (0.6)	0
Pharyngitis bacterial	1 (0.2)	0	0
Rash pustular	1 (0.2)	0	0
Tonsillitis bacterial	1 (0.2)	0	0
Tracheitis	1 (0.2)	2 (1.1)	1 (0.4)

Supplementary Table SII. Cont.

Primary System Organ Class Preferred term, n (%) of patients	High-intensity statin (n = 580)	Low/moderate-inten- sity statin (n = 181)	No statin (n = 233)
Urinary tract infection bacterial	1 (0.2)	0	0
Urosepsis	1 (0.2)	0	0
Varicella	1 (0.2)	0	0
Vestibular neuronitis	1 (0.2)	0	0
Vulvovaginal candidiasis	1 (0.2)	0	0
Wound infection	1 (0.2)	0	0
Appendicitis	0	0	1 (0.4)
Carbuncle	0	0	1 (0.4)
Diabetic foot infection	0	0	1 (0.4)
Dysentery	0	1 (0.6)	0
Erysipelas	0	1 (0.6)	0
Gastrointestinal fungal infection	0	0	1 (0.4)
Genital herpes	0	0	1 (0.4)
Helminthic infection	0	0	1 (0.4)
Liver abscess	0	0	1 (0.4)
Lower respiratory tract infection	0	1 (0.6)	0
Mononucleosis syndrome	0	0	1 (0.4)
Onychomycosis	0	0	2 (0.9)
Oral candidiasis	0	1 (0.6)	2 (0.9)
Oral fungal infection	0	1 (0.6)	0
Parotitis	0	1 (0.6)	0
Pharyngotonsillitis	0	1 (0.6)	0
Pleurisy viral	0	1 (0.6)	0
Pyelonephritis	0	0	1 (0.4)
Respiratory tract infection bacterial	0	0	2 (0.9)
Toxoplasmosis	0	0	1 (0.4)
Tracheobronchitis	0	1 (0.6)	0
Viral sinusitis	0	0	1 (0.4)
Viral tonsillitis	0	0	1 (0.4)
Neoplasms benign, malignant, and unspecified (incl. cysts and polyps):	10 (1.7)	4 (2.2)	6 (2.6)
Breast cancer	1 (0.2)	0	0
Clear cell renal cell carcinoma	1 (0.2)	0	0
Colon adenoma	1 (0.2)	0	0
Lipoma	1 (0.2)	1 (0.6)	0
Lung adenocarcinoma	1 (0.2)	1 (0.6)	0
Myelodysplastic syndrome	1 (0.2)	0	0
Prostatic adenoma	1 (0.2)	0	0
Tendon neoplasm	1 (0.2)	0	0
Transitional cell carcinoma	1 (0.2)	0	0
Uterine cancer	1 (0.2)	0	0
Benign neoplasm of prostate	0	0	1 (0.4)
Bladder cancer stage 0, with cancer in situ	0	0	1 (0.4)
Gastrointestinal tract adenoma	0	1 (0.6)	0
Lentigo maligna	0	1 (0.6)	0

Supplementary Table SII. Cont.

Primary System Organ Class Preferred term, n (%) of patients	High-intensity statin (n = 580)	Low/moderate-inten- sity statin (n = 181)	No statin (n = 233)
Pleomorphic adenoma	0	0	1 (0.4)
Prostate cancer	0	0	3 (1.3)
Rectal adenocarcinoma	0	0	1 (0.4)
Skin papilloma	0	1 (0.6)	0
Blood and lymphatic system disorders:	11 (1.9)	4 (2.2)	8 (3.4)
Anemia	6 (1.0)	1 (0.6)	4 (1.7)
Neutropenia	3 (0.5)	1 (0.6)	3 (1.3)
Hypochromic anemia	1 (0.2)	0	0
Leukopenia	1 (0.2)	0	0
Thrombocytopenia	1 (0.2)	1 (0.6)	2 (0.9)
Idiopathic neutropenia	0	1 (0.6)	0
Lymphadenopathy	0	1 (0.6)	0
Immune system disorders:	7 (1.2)	1 (0.6)	1 (0.4)
Allergy to arthropod sting	2 (0.3)	1 (0.6)	0
Hypersensitivity	2 (0.3)	0	0
Seasonal allergy	2 (0.3)	0	0
Allergy to arthropod bite	1 (0.2)	0	0
Drug hypersensitivity	0	0	1 (0.4)
Endocrine disorders:	5 (0.9)	1 (0.6)	2 (0.9)
Hypothyroidism	2 (0.3)	0	2 (0.9)
Goitre	1 (0.2)	0	0
Hyperadrenalism	1 (0.2)	0	0
Hyperthyroidism	1 (0.2)	0	0
Hyperparathyroidism	0	1 (0.6)	0
Metabolism and nutrition disorders:	23 (4.0)	13 (7.2)	24 (10.3)
Diabetes mellitus	7 (1.2)	3 (1.7)	1 (0.4)
Decreased appetite	2 (0.3)	3 (1.7)	2 (0.9)
Glucose tolerance impaired	2 (0.3)	1 (0.6)	0
Gout	2 (0.3)	0	4 (1.7)
Hyperglycemia	2 (0.3)	1 (0.6)	2 (0.9)
Type 2 diabetes mellitus	2 (0.3)	2 (1.1)	2 (0.9)
Dehydration	1 (0.2)	0	0
Diabetes mellitus inadequate control	1 (0.2)	0	5 (2.1)
Fluid retention	1 (0.2)	0	0
Hyperkalemia	1 (0.2)	0	2 (0.9)
Hypertriglyceridemia	1 (0.2)	0	2 (0.9)
Hyperuricemia	1 (0.2)	0	3 (1.3)
Hypokalemia	1 (0.2)	0	0
Impaired fasting glucose	1 (0.2)	0	0
Metabolic syndrome	1 (0.2)	0	0
Hypocalcemia	0	1 (0.6)	0
Hypoglycemia	0	1 (0.6)	1 (0.4)
Hypomagnesaemia	0	1 (0.6)	0
Hyponatremia	0	0	1 (0.4)
Increased appetite	0	1 (0.6)	0
Vitamin B ₁₂ deficiency	0	0	1 (0.4)
Vitamin D deficiency	0	0	2 (0.9)

Supplementary Table SII. Cont.

Primary System Organ Class Preferred term, n (%) of patients	High-intensity statin (n = 580)	Low/moderate-inten- sity statin (n = 181)	No statin (n = 233)
Psychiatric disorders:	22 (3.8)	10 (5.5)	14 (6.0)
Insomnia	7 (1.2)	3 (1.7)	3 (1.3)
Depression	5 (0.9)	2 (1.1)	1 (0.4)
Anxiety	3 (0.5)	2 (1.1)	4 (1.7)
Anxiety disorder	2 (0.3)	0	0
Apathy	1 (0.2)	0	0
Confusional state	1 (0.2)	1 (0.6)	1 (0.4)
Disorganized speech	1 (0.2)	0	0
Irritability	1 (0.2)	0	0
Mental disorder	1 (0.2)	0	0
Psychological trauma	1 (0.2)	0	0
Schizophrenia	1 (0.2)	0	0
Stress	1 (0.2)	0	1 (0.4)
Suicide attempt	1 (0.2)	0	0
Completed suicide	0	1 (0.6)	0
Depressive symptom	0	0	1 (0.4)
Hallucination	0	0	1 (0.4)
Libido decreased	0	0	1 (0.4)
Middle insomnia	0	1 (0.6)	0
Sleep disorder	0	1 (0.6)	1 (0.4)
Nervous system disorders:	63 (10.9)	26 (14.4)	59 (25.3)
Headache	22 (3.8)	18 (9.9)	22 (9.4)
Dizziness	9 (1.6)	2 (1.1)	7 (3.0)
Hypoesthesia	4 (0.7)	1 (0.6)	0
Sciatica	4 (0.7)	1 (0.6)	5 (2.1)
Amnesia	3 (0.5)	0	0
Presyncope	3 (0.5)	1 (0.6)	3 (1.3)
Syncope	3 (0.5)	0	4 (1.7)
Carotid artery stenosis	2 (0.3)	0	4 (1.7)
Dysgeusia	2 (0.3)	0	1 (0.4)
Paresthesia	2 (0.3)	0	4 (1.7)
Balance disorder	1 (0.2)	0	1 (0.4)
Carpal tunnel syndrome	1 (0.2)	0	3 (1.3)
Cerebrovascular accident	1 (0.2)	0	0
Cervicobrachial syndrome	1 (0.2)	0	0
Complex regional pain syndrome	1 (0.2)	0	0
Disturbance in attention	1 (0.2)	0	1 (0.4)
Dizziness postural	1 (0.2)	0	0
Facial neuralgia	1 (0.2)	0	0
Ischemic cerebral infarction	1 (0.2)	0	0
Ischemic stroke	1 (0.2)	0	0
Memory impairment	1 (0.2)	1 (0.6)	0
Migraine	1 (0.2)	1 (0.6)	2 (0.9)
Perineurial cyst	1 (0.2)	0	0
Peripheral sensorimotor neuropathy	1 (0.2)	0	0
Tension headache	1 (0.2)	0	0

Supplementary Table SII. Cont.

Primary System Organ Class Preferred term, n (%) of patients	High-intensity statin (n = 580)	Low/moderate-inten- sity statin (n = 181)	No statin (n = 233)
Transient ischemic attack	1 (0.2)	0	2 (0.9)
Ataxia	0	1 (0.6)	0
Burning sensation	0	0	2 (0.9)
Cluster headache	0	1 (0.6)	0
Diabetic neuropathy	0	0	1 (0.4)
Facial paralysis	0	1 (0.6)	0
Head discomfort	0	1 (0.6)	0
Hypokinesia	0	0	1 (0.4)
Intention tremor	0	0	1 (0.4)
Lethargy	0	0	1 (0.4)
Nerve compression	0	0	1 (0.4)
Neuralgia	0	0	1 (0.4)
Neuropathy peripheral	0	1 (0.6)	2 (0.9)
Restless legs syndrome	0	1 (0.6)	0
Seizure	0	1 (0.6)	0
Thoracic outlet syndrome	0	0	1 (0.4)
Visual field defect	0	0	1 (0.4)
Eye disorders:	11 (1.9)	14 (7.7)	20 (8.6)
Eye pruritus	2 (0.3)	0	0
Cataract	1 (0.2)	3 (1.7)	4 (1.7)
Dacryostenosis acquired	1 (0.2)	0	0
Dry eye	1 (0.2)	0	3 (1.3)
Eye inflammation	1 (0.2)	0	0
Eye pain	1 (0.2)	0	2 (0.9)
Ocular hyperemia	1 (0.2)	0	0
Retinal hemorrhage	1 (0.2)	0	0
Swelling of eyelid	1 (0.2)	0	0
Vitreous detachment	1 (0.2)	0	0
Amaurosis fugax	0	0	1 (0.4)
Arcus lipoides	0	0	1 (0.4)
Blepharitis	0	2 (1.1)	0
Conjunctival hemorrhage	0	2 (1.1)	0
Conjunctival hyperemia	0	1 (0.6)	0
Conjunctivitis allergic	0	1 (0.6)	1 (0.4)
Diplopia	0	0	1 (0.4)
Eye allergy	0	0	1 (0.4)
Eye irritation	0	0	1 (0.4)
Eyelid ptosis	0	0	1 (0.4)
Halo vision	0	0	1 (0.4)
Lacrimation increased	0	1 (0.6)	0
Maculopathy	0	1 (0.6)	0
Retinal tear	0	1 (0.6)	0
Scleritis	0	0	1 (0.4)
Vision blurred	0	1 (0.6)	2 (0.9)
Visual acuity reduced	0	0	1 (0.4)
Visual impairment	0	1 (0.6)	1 (0.4)

Supplementary Table SII. Cont.

Primary System Organ Class Preferred term, n (%) of patients	High-intensity statin (n = 580)	Low/moderate-inten- sity statin (n = 181)	No statin (n = 233)
Ear and labyrinth disorders:	11 (1.9)	4 (2.2)	11 (4.7)
Vertigo	5 (0.9)	2 (1.1)	5 (2.1)
Tinnitus	2 (0.3)	0	0
Vertigo positional	2 (0.3)	1 (0.6)	2 (0.9)
Excessive cerumen production	1 (0.2)	0	0
Otosclerosis	1 (0.2)	0	0
Ear discomfort	0	0	2 (0.9)
Ear pain	0	1 (0.6)	1 (0.4)
Meniere's disease	0	0	1 (0.4)
Cardiac disorders:	53 (9.1)	15 (8.3)	39 (16.7)
Angina pectoris	16 (2.8)	6 (3.3)	12 (5.2)
Angina unstable	8 (1.4)	1 (0.6)	4 (1.7)
Acute myocardial infarction	4 (0.7)	0	1 (0.4)
Atrial fibrillation	4 (0.7)	1 (0.6)	3 (1.3)
Coronary artery disease	4 (0.7)	0	4 (1.7)
Coronary artery stenosis	4 (0.7)	2 (1.1)	3 (1.3)
Cardiac failure	3 (0.5)	2 (1.1)	2 (0.9)
Myocardial infarction	3 (0.5)	0	0
Palpitations	3 (0.5)	3 (1.7)	2 (0.9)
Acute coronary syndrome	2 (0.3)	0	3 (1.3)
Bradycardia	2 (0.3)	0	1 (0.4)
Myocardial ischemia	2 (0.3)	0	5 (2.1)
Pericarditis	2 (0.3)	0	0
Aortic valve stenosis	1 (0.2)	0	0
Arrhythmia	1 (0.2)	0	0
Arteriosclerosis coronary artery	1 (0.2)	0	0
Atrial tachycardia	1 (0.2)	0	0
Atrioventricular block second degree	1 (0.2)	0	2 (0.9)
Cardiac failure chronic	1 (0.2)	0	0
Cardiac failure congestive	1 (0.2)	0	0
Mitral valve stenosis	1 (0.2)	0	0
Subendocardial ischemia	1 (0.2)	0	0
Tachycardia	1 (0.2)	0	1 (0.4)
Atrial flutter	0	0	1 (0.4)
Coronary ostial stenosis	0	0	1 (0.4)
Ventricular extrasystoles	0	1 (0.6)	1 (0.4)
Ventricular fibrillation	0	0	1 (0.4)
Vascular disorders:	45 (7.8)	15 (8.3)	30 (12.9)
Hypertension	20 (3.4)	7 (3.9)	13 (5.6)
Hypotension	7 (1.2)	2 (1.1)	5 (2.1)
Hematoma	4 (0.7)	0	1 (0.4)
Peripheral arterial occlusive disease	3 (0.5)	2 (1.1)	0
Aortic aneurysm	2 (0.3)	0	0
Peripheral artery stenosis	2 (0.3)	0	2 (0.9)
Thrombophlebitis	2 (0.3)	0	0
Aortic dilatation	1 (0.2)	0	0

Supplementary Table SII. Cont.

Primary System Organ Class Preferred term, n (%) of patients	High-intensity statin (n = 580)	Low/moderate-inten- sity statin (n = 181)	No statin (n = 233)
Aortic dissection	1 (0.2)	0	0
Aortic stenosis	1 (0.2)	0	0
Circulatory collapse	1 (0.2)	0	0
Deep vein thrombosis	1 (0.2)	0	1 (0.4)
Hemorrhage	1 (0.2)	0	0
Hypertensive crisis	1 (0.2)	0	1 (0.4)
Peripheral artery aneurysm	1 (0.2)	0	0
Arteritis	0	1 (0.6)	0
Flushing	0	0	1 (0.4)
Hot flush	0	1 (0.6)	3 (1.3)
Intermittent claudication	0	1 (0.6)	1 (0.4)
Peripheral artery thrombosis	0	0	1 (0.4)
Peripheral coldness	0	0	1 (0.4)
Varicose vein	0	1 (0.6)	0
Respiratory, thoracic, and mediastinal disorders:	42 (7.2)	19 (10.5)	28 (12.0)
Cough	9 (1.6)	2 (1.1)	6 (2.6)
Dyspnea	6 (1.0)	6 (3.3)	5 (2.1)
Epistaxis	6 (1.0)	1 (0.6)	2 (0.9)
Dyspnea exertional	4 (0.7)	0	2 (0.9)
Oropharyngeal pain	4 (0.7)	1 (0.6)	4 (1.7)
Dysphonia	2 (0.3)	0	0
Rhinitis allergic	2 (0.3)	3 (1.7)	2 (0.9)
Rhinorrhea	2 (0.3)	0	1 (0.4)
Asthma	1 (0.2)	1 (0.6)	2 (0.9)
Choking sensation	1 (0.2)	0	0
Chronic obstructive pulmonary disease	1 (0.2)	1 (0.6)	1 (0.4)
Dry throat	1 (0.2)	0	1 (0.4)
Emphysema	1 (0.2)	0	0
Lung disorder	1 (0.2)	0	1 (0.4)
Nasal pruritus	1 (0.2)	0	0
Pulmonary mass	1 (0.2)	0	0
Sneezing	1 (0.2)	1 (0.6)	0
Allergic bronchitis	0	1 (0.6)	0
Allergic cough	0	0	1 (0.4)
Asthmatic crisis	0	0	1 (0.4)
Bronchiectasis	0	0	1 (0.4)
Bronchitis chronic	0	0	1 (0.4)
Hemoptysis	0	0	1 (0.4)
Laryngeal edema	0	1 (0.6)	0
Nasal obstruction	0	1 (0.6)	0
Productive cough	0	1 (0.6)	0
Pulmonary embolism	0	0	1 (0.4)
Sleep apnea syndrome	0	0	4 (1.7)
Snoring	0	1 (0.6)	0

Supplementary Table SII. Cont.

Primary System Organ Class Preferred term, n (%) of patients	High-intensity statin (n = 580)	Low/moderate-inten- sity statin (n = 181)	No statin (n = 233)
Gastrointestinal disorders:	72 (12.4)	35 (19.3)	65 (27.9)
Diarrhea	18 (3.1)	12 (6.6)	15 (6.4)
Abdominal pain	8 (1.4)	1 (0.6)	6 (2.6)
Nausea	8 (1.4)	5 (2.8)	9 (3.9)
Abdominal pain upper	6 (1.0)	5 (2.8)	5 (2.1)
Constipation	6 (1.0)	5 (2.8)	8 (3.4)
Dry mouth	4 (0.7)	1 (0.6)	1 (0.4)
Gastroesophageal reflux disease	4 (0.7)	1 (0.6)	3 (1.3)
Dyspepsia	3 (0.5)	2 (1.1)	2 (0.9)
Vomiting	3 (0.5)	0	6 (2.6)
Abdominal distension	2 (0.3)	0	1 (0.4)
Colitis	2 (0.3)	0	1 (0.4)
Flatulence	2 (0.3)	0	4 (1.7)
Hemorrhoidal hemorrhage	2 (0.3)	0	2 (0.9)
Hemorrhoids	2 (0.3)	2 (1.1)	1 (0.4)
Inguinal hernia	2 (0.3)	0	3 (1.3)
Mouth ulceration	2 (0.3)	0	0
Stomatitis	2 (0.3)	1 (0.6)	0
Umbilical hernia	2 (0.3)	0	0
Anal fissure	1 (0.2)	0	0
Anal pruritus	1 (0.2)	0	0
Anorectal discomfort	1 (0.2)	0	0
Aphthous ulcer	1 (0.2)	0	0
Breath odor	1 (0.2)	0	0
Chronic gastritis	1 (0.2)	0	0
Colitis ischemic	1 (0.2)	0	0
Dental cyst	1 (0.2)	0	0
Diverticulum intestinal	1 (0.2)	1 (0.6)	0
Duodenitis	1 (0.2)	0	0
Enteritis	1 (0.2)	0	0
Feces soft	1 (0.2)	0	0
Gastric disorder	1 (0.2)	0	0
Gastritis	1 (0.2)	0	3 (1.3)
Hemorrhoids thrombosed	1 (0.2)	0	0
Hernial eventration	1 (0.2)	0	0
Hiatus hernia	1 (0.2)	0	0
Intra-abdominal hematoma	1 (0.2)	0	0
Irritable bowel syndrome	1 (0.2)	0	2 (0.9)
Large intestine polyp	1 (0.2)	0	0
Noninfective gingivitis	1 (0.2)	0	0
Esophagitis	1 (0.2)	0	1 (0.4)
Oral discomfort	1 (0.2)	0	0
Oral lichen planus	1 (0.2)	0	0
Oral mucosal eruption	1 (0.2)	0	1 (0.4)
Oral pruritus	1 (0.2)	0	0
Pigmentation lip	1 (0.2)	0	0

Supplementary Table SII. Cont.

Primary System Organ Class Preferred term, n (%) of patients	High-intensity statin (n = 580)	Low/moderate-inten- sity statin (n = 181)	No statin (n = 233)
Proctalgia	1 (0.2)	0	0
Salivary hypersecretion	1 (0.2)	0	0
Tongue dry	1 (0.2)	0	0
Toothache	1 (0.2)	1 (0.6)	1 (0.4)
Abdominal discomfort	0	2 (1.1)	0
Abdominal rigidity	0	1 (0.6)	0
Abdominal wall hematoma	0	1 (0.6)	1 (0.4)
Coeliac artery compression syndrome	0	0	1 (0.4)
Dental caries	0	1 (0.6)	0
Dental necrosis	0	1 (0.6)	0
Diverticular perforation	0	0	1 (0.4)
Diverticulum	0	1 (0.6)	1 (0.4)
Duodenogastric reflux	0	1 (0.6)	0
Enterocolitis hemorrhagic	0	0	1 (0.4)
Eructation	0	0	2 (0.9)
Feces pale	0	0	1 (0.4)
Fistula of small intestine	0	1 (0.6)	0
Food poisoning	0	1 (0.6)	1 (0.4)
Gastrointestinal disorder	0	1 (0.6)	2 (0.9)
Hematemesis	0	0	1 (0.4)
Hypoesthesia oral	0	0	1 (0.4)
Lower gastrointestinal hemorrhage	0	1 (0.6)	0
Melaena	0	0	1 (0.4)
Palatal disorder	0	0	1 (0.4)
Palatal edema	0	1 (0.6)	0
Perianal erythema	0	1 (0.6)	0
Rectal hemorrhage	0	2 (1.1)	0
Tooth loss	0	0	1 (0.4)
Hepatobiliary disorders:	9 (1.6)	4 (2.2)	2 (0.9)
Cholelithiasis	2 (0.3)	0	0
Hepatic steatosis	2 (0.3)	3 (1.7)	0
Hepatocellular injury	2 (0.3)	0	1 (0.4)
Hepatic mass	1 (0.2)	0	0
Hepatomegaly	1 (0.2)	0	0
Hypertransaminasemia	1 (0.2)	0	0
Bile duct stone	0	1 (0.6)	0
Cholestasis	0	0	1 (0.4)
Chronic hepatitis	0	0	1 (0.4)
Skin and subcutaneous tissue disorders:	46 (7.9)	15 (8.3)	35 (15.0)
Pruritus	8 (1.4)	2 (1.1)	7 (3.0)
Rash	6 (1.0)	2 (1.1)	4 (1.7)
Erythema	5 (0.9)	4 (2.2)	3 (1.3)
Alopecia	4 (0.7)	0	0
Eczema	3 (0.5)	1 (0.6)	2 (0.9)
Urticaria	3 (0.5)	2 (1.1)	0

Supplementary Table SII. Cont.

Primary System Organ Class Preferred term, n (%) of patients	High-intensity statin (n = 580)	Low/moderate-inten- sity statin (n = 181)	No statin (n = 233)
Dry skin	2 (0.3)	1 (0.6)	2 (0.9)
Ecchymosis	2 (0.3)	1 (0.6)	1 (0.4)
Pruritus generalized	2 (0.3)	0	3 (1.3)
Actinic keratosis	1 (0.2)	0	0
Dermal cyst	1 (0.2)	0	0
Dermatitis contact	1 (0.2)	0	0
Drug eruption	1 (0.2)	0	0
Hyperkeratosis	1 (0.2)	0	0
Nail discomfort	1 (0.2)	0	0
Parapsoriasis	1 (0.2)	0	0
Petechiae	1 (0.2)	0	0
Pigmentation disorder	1 (0.2)	0	0
Rosacea	1 (0.2)	0	1 (0.4)
Scar pain	1 (0.2)	0	0
Skin hyperpigmentation	1 (0.2)	0	0
Skin irritation	1 (0.2)	0	0
Skin mass	1 (0.2)	0	1 (0.4)
Skin plaque	1 (0.2)	0	0
Swelling face	1 (0.2)	0	1 (0.4)
Xanthoma	1 (0.2)	1 (0.6)	0
Dermatitis	0	0	1 (0.4)
Dermatitis allergic	0	0	2 (0.9)
Fracture blisters	0	0	1 (0.4)
Generalized erythema	0	1 (0.6)	0
Hyperhidrosis	0	1 (0.6)	0
Night sweats	0	1 (0.6)	1 (0.4)
Peau d'orange	0	0	1 (0.4)
Purpura	0	0	1 (0.4)
Rash pruritic	0	0	1 (0.4)
Skin burning sensation	0	0	1 (0.4)
Skin lesion	0	0	1 (0.4)
Skin reaction	0	0	1 (0.4)
Musculoskeletal and connective tissue disorders:	97 (16.7)	54 (29.8)	87 (37.3)
Myalgia	26 (4.5)	20 (11.0)	25 (10.7)
Back pain	25 (4.3)	10 (5.5)	7 (3.0)
Pain in extremity	17 (2.9)	6 (3.3)	16 (6.9)
Arthralgia	10 (1.7)	12 (6.6)	14 (6.0)
Muscle spasms	8 (1.4)	9 (5.0)	17 (7.3)
Tendonitis	6 (1.0)	3 (1.7)	4 (1.7)
Musculoskeletal pain	5 (0.9)	1 (0.6)	8 (3.4)
Intervertebral disc protrusion	3 (0.5)	1 (0.6)	2 (0.9)
Rheumatic disorder	3 (0.5)	0	0
Spinal osteoarthritis	3 (0.5)	0	1 (0.4)
Arthritis	2 (0.3)	1 (0.6)	1 (0.4)
Gouty arthritis	2 (0.3)	2 (1.1)	1 (0.4)

Supplementary Table SII. Cont.

Primary System Organ Class Preferred term, n (%) of patients	High-intensity statin (n = 580)	Low/moderate-inten- sity statin (n = 181)	No statin (n = 233)
Musculoskeletal stiffness	2 (0.3)	0	1 (0.4)
Neck pain	2 (0.3)	1 (0.6)	5 (2.1)
Osteoarthritis	2 (0.3)	3 (1.7)	5 (2.1)
Synovial cyst	2 (0.3)	0	0
Tendon pain	2 (0.3)	0	2 (0.9)
Bursa calcification	1 (0.2)	0	0
Fibromyalgia	1 (0.2)	1 (0.6)	0
Intervertebral disc disorder	1 (0.2)	0	0
Joint effusion	1 (0.2)	0	0
Joint lock	1 (0.2)	0	0
Joint range of motion decreased	1 (0.2)	0	0
Muscle twitching	1 (0.2)	0	0
Muscular weakness	1 (0.2)	1 (0.6)	2 (0.9)
Musculoskeletal chest pain	1 (0.2)	0	1 (0.4)
Osteoporosis	1 (0.2)	0	0
Plantar fasciitis	1 (0.2)	0	1 (0.4)
Polymyalgia rheumatica	1 (0.2)	0	1 (0.4)
Rotator cuff syndrome	1 (0.2)	2 (1.1)	0
Spondylolisthesis	1 (0.2)	0	0
Tendon disorder	1 (0.2)	0	0
Tenosynovitis stenosans	1 (0.2)	0	0
Ankylosing spondylitis	0	0	1 (0.4)
Bone pain	0	1 (0.6)	1 (0.4)
Exostosis	0	1 (0.6)	0
Flank pain	0	0	1 (0.4)
Hemarthrosis	0	1 (0.6)	0
Joint noise	0	1 (0.6)	0
Joint stiffness	0	1 (0.6)	0
Ligamentum flavum hypertrophy	0	0	1 (0.4)
Limb discomfort	0	1 (0.6)	0
Muscle tightness	0	0	1 (0.4)
Musculoskeletal discomfort	0	2 (1.1)	0
Myopathy	0	0	1 (0.4)
Myopathy toxic	0	1 (0.6)	0
Myositis	0	0	3 (1.3)
Nuchal rigidity	0	0	1 (0.4)
Osteochondrosis	0	0	1 (0.4)
Osteopenia	0	1 (0.6)	0
Pain in jaw	0	0	1 (0.4)
Rheumatoid arthritis	0	0	1 (0.4)
Spinal column stenosis	0	0	1 (0.4)
Spinal pain	0	0	2 (0.9)
Renal and urinary disorders:	12 (2.1)	1 (0.6)	10 (4.3)
Hematuria	3 (0.5)	0	0
Renal colic	3 (0.5)	0	2 (0.9)
Dysuria	2 (0.3)	1 (0.6)	2 (0.9)

Supplementary Table SII. Cont.

Primary System Organ Class Preferred term, n (%) of patients	High-intensity statin (n = 580)	Low/moderate-inten- sity statin (n = 181)	No statin (n = 233)
Renal impairment	2 (0.3)	0	0
Nocturia	1 (0.2)	0	0
Pyelocaliectasis	1 (0.2)	0	0
Renal disorder	1 (0.2)	0	0
Acute kidney injury	0	0	1 (0.4)
Bladder trabeculation	0	0	1 (0.4)
Cystitis noninfective	0	0	1 (0.4)
Diabetic nephropathy	0	0	1 (0.4)
Nephrolithiasis	0	0	1 (0.4)
Urinary retention	0	0	1 (0.4)
Pregnancy, puerperium, and perinatal conditions:	0	0	1 (0.4)
Pregnancy	0	0	1 (0.4)
Reproductive system and breast disorders:	9 (1.6)	6 (3.3)	9 (3.9)
Metrorrhagia	2 (0.3)	0	0
Prostatitis	2 (0.3)	0	4 (1.7)
Benign prostatic hyperplasia	1 (0.2)	1 (0.6)	0
Fibrocystic breast disease	1 (0.2)	0	0
Scrotal pain	1 (0.2)	0	0
Testicular pain	1 (0.2)	0	0
Testicular swelling	1 (0.2)	0	0
Uterine polyp	1 (0.2)	0	1 (0.4)
Breast calcifications	0	1 (0.6)	0
Breast pain	0	0	1 (0.4)
Dysmenorrhea	0	1 (0.6)	0
Endometrial hypertrophy	0	0	1 (0.4)
Erectile dysfunction	0	2 (1.1)	2 (0.9)
Pelvic pain	0	0	1 (0.4)
Vulvar dysplasia	0	1 (0.6)	0
Congenital, familial, and genetic disorders:	1 (0.2)	1 (0.6)	1 (0.4)
Congenital cystic kidney disease	1 (0.2)	0	0
Accessory navicular syndrome	0	1 (0.6)	0
Glycogen storage disease type V	0	0	1 (0.4)
General disorders and administration-site conditions:	113 (19.5)	62 (34.3)	99 (42.5)
Injection-site reaction	17 (2.9)	19 (10.5)	13 (5.6)
Injection-site hematoma	16 (2.8)	12 (6.6)	15 (6.4)
Injection-site swelling	14 (2.4)	5 (2.8)	12 (5.2)
Asthenia	12 (2.1)	8 (4.4)	19 (8.2)
Injection-site erythema	12 (2.1)	8 (4.4)	18 (7.7)
Injection-site pain	10 (1.7)	5 (2.8)	11 (4.7)
Non-cardiac chest pain	8 (1.4)	4 (2.2)	13 (5.6)
Edema peripheral	7 (1.2)	1 (0.6)	2 (0.9)
Pyrexia	7 (1.2)	2 (1.1)	3 (1.3)
Fatigue	6 (1.0)	7 (3.9)	16 (6.9)

Supplementary Table SII. Cont.

Primary System Organ Class Preferred term, n (%) of patients	High-intensity statin (n = 580)	Low/moderate-inten- sity statin (n = 181)	No statin (n = 233)
Influenza-like illness	5 (0.9)	3 (1.7)	6 (2.6)
Injection-site bruising	5 (0.9)	4 (2.2)	5 (2.1)
Injection-site hemorrhage	5 (0.9)	4 (2.2)	8 (3.4)
Injection-site pruritus	5 (0.9)	4 (2.2)	4 (1.7)
Chest pain	3 (0.5)	0	3 (1.3)
Injection-site induration	3 (0.5)	0	3 (1.3)
Pain	3 (0.5)	1 (0.6)	1 (0.4)
Peripheral swelling	3 (0.5)	0	0
Cyst	2 (0.3)	0	0
Swelling	2 (0.3)	0	0
Vascular stent stenosis	2 (0.3)	0	2 (0.9)
Adverse drug reaction	1 (0.2)	0	0
Adverse reaction	1 (0.2)	0	0
Discomfort	1 (0.2)	1 (0.6)	1 (0.4)
Feeling cold	1 (0.2)	0	1 (0.4)
Hyperpyrexia	1 (0.2)	1 (0.6)	0
Hyperthermia	1 (0.2)	0	0
Injection-site hypersensitivity	1 (0.2)	3 (1.7)	0
Injection-site mass	1 (0.2)	0	1 (0.4)
Injection-site edema	1 (0.2)	0	1 (0.4)
Injection-site warmth	1 (0.2)	1 (0.6)	0
Puncture-site reaction	1 (0.2)	0	0
Vessel puncture site hematoma	1 (0.2)	0	0
Application site hemorrhage	0	0	1 (0.4)
Chest discomfort	0	1 (0.6)	2 (0.9)
Chills	0	1 (0.6)	2 (0.9)
Drug intolerance	0	1 (0.6)	1 (0.4)
Face edema	0	0	1 (0.4)
Inflammation	0	1 (0.6)	0
Infusion site erythema	0	0	1 (0.4)
Injection-site discoloration	0	1 (0.6)	0
Injection-site irritation	0	2 (1.1)	0
Injection-site papule	0	1 (0.6)	0
Injection-site paresthesia	0	0	1 (0.4)
Injection-site urticaria	0	2 (1.1)	0
Malaise	0	0	1 (0.4)
Puncture-site edema	0	0	1 (0.4)
Thirst	0	0	1 (0.4)
Investigations:	39 (6.7)	20 (11.0)	24 (10.3)
Alanine aminotransferase increased	8 (1.4)	1 (0.6)	2 (0.9)
Blood creatine phosphokinase increased	5 (0.9)	8 (4.4)	7 (3.0)
Blood pressure increased	4 (0.7)	2 (1.1)	2 (0.9)
Blood glucose increased	3 (0.5)	0	3 (1.3)
Gamma-glutamyltransferase increased	3 (0.5)	0	2 (0.9)

Supplementary Table SII. Cont.

Primary System Organ Class Preferred term, n (%) of patients	High-intensity statin (n = 580)	Low/moderate-inten- sity statin (n = 181)	No statin (n = 233)
Low-density lipoprotein decreased	3 (0.5)	3 (1.7)	1 (0.4)
Transaminases increased	3 (0.5)	3 (1.7)	1 (0.4)
Aspartate aminotransferase increased	2 (0.3)	1 (0.6)	1 (0.4)
Blood bilirubin increased	2 (0.3)	0	1 (0.4)
Blood uric acid increased	2 (0.3)	0	0
Platelet count decreased	2 (0.3)	0	0
Arterial bruit	1 (0.2)	0	0
Blood creatinine increased	1 (0.2)	0	1 (0.4)
Blood glucose abnormal	1 (0.2)	0	1 (0.4)
Blood lactate dehydrogenase increased	1 (0.2)	0	0
Blood pressure systolic increased	1 (0.2)	0	0
Blood triglycerides abnormal	1 (0.2)	0	0
Breath sounds abnormal	1 (0.2)	0	0
Cardiac stress test abnormal	1 (0.2)	0	1 (0.4)
Gamma-glutamyltransferase abnormal	1 (0.2)	0	0
Glycosylated hemoglobin increased	1 (0.2)	0	2 (0.9)
Heart rate increased	1 (0.2)	0	1 (0.4)
Low density lipoprotein increased	1 (0.2)	0	0
Platelet count increased	1 (0.2)	0	0
Red blood cell count decreased	1 (0.2)	0	0
Weight decreased	1 (0.2)	0	1 (0.4)
Weight increased	1 (0.2)	0	1 (0.4)
White blood cell count increased	1 (0.2)	0	0
White blood cells urine positive	1 (0.2)	0	0
Blood pressure abnormal	0	1 (0.6)	0
Blood triglycerides increased	0	0	1 (0.4)
Blood urea increased	0	0	1 (0.4)
Cardiac murmur	0	0	1 (0.4)
Eosinophil count increased	0	0	1 (0.4)
Hemoglobin decreased	0	2 (1.1)	0
International normalized ratio increased	0	0	1 (0.4)
Muscle enzyme increased	0	0	1 (0.4)
Waist circumference increased	0	1 (0.6)	0
Injury, poisoning, and procedural complications:	46 (7.9)	22 (12.2)	22 (9.4)
Fall	7 (1.2)	4 (2.2)	2 (0.9)
Contusion	4 (0.7)	1 (0.6)	1 (0.4)
Tendon rupture	4 (0.7)	0	3 (1.3)
Joint dislocation	3 (0.5)	0	0
Ligament sprain	3 (0.5)	3 (1.7)	1 (0.4)
Accidental overdose	2 (0.3)	1 (0.6)	2 (0.9)
Limb injury	2 (0.3)	0	1 (0.4)
Lower limb fracture	2 (0.3)	0	0
Meniscus injury	2 (0.3)	1 (0.6)	0

Supplementary Table SII. Cont.

Primary System Organ Class Preferred term, n (%) of patients	High-intensity statin (n = 580)	Low/moderate-inten- sity statin (n = 181)	No statin (n = 233)
Radius fracture	2 (0.3)	0	1 (0.4)
Sunburn	2 (0.3)	1 (0.6)	0
Upper limb fracture	2 (0.3)	2 (1.1)	1 (0.4)
Animal bite	1 (0.2)	0	0
Ankle fracture	1 (0.2)	2 (1.1)	0
Arthropod bite	1 (0.2)	1 (0.6)	1 (0.4)
Bone fissure	1 (0.2)	0	0
Dental restoration failure	1 (0.2)	0	0
Epicondylitis	1 (0.2)	0	0
Face injury	1 (0.2)	0	0
Hand fracture	1 (0.2)	2 (1.1)	0
Injury	1 (0.2)	0	0
Kidney contusion	1 (0.2)	0	0
Lumbar vertebral fracture	1 (0.2)	0	0
Muscle injury	1 (0.2)	0	0
Procedural headache	1 (0.2)	1 (0.6)	0
Procedural nausea	1 (0.2)	1 (0.6)	1 (0.4)
Rib fracture	1 (0.2)	0	2 (0.9)
Spinal column injury	1 (0.2)	0	0
Subcutaneous hematoma	1 (0.2)	0	0
Tooth fracture	1 (0.2)	0	0
Vascular graft occlusion	1 (0.2)	0	0
Vascular pseudoaneurysm	1 (0.2)	0	0
Wrist fracture	1 (0.2)	0	1 (0.4)
Arthropod sting	0	1 (0.6)	0
Electric shock	0	1 (0.6)	0
Eye injury	0	0	1 (0.4)
Facial bones fracture	0	0	1 (0.4)
Foot fracture	0	1 (0.6)	0
Gingival injury	0	0	1 (0.4)
Hip fracture	0	1 (0.6)	0
Humerus fracture	0	1 (0.6)	0
Intentional overdose	0	0	1 (0.4)
Joint injury	0	1 (0.6)	2 (0.9)
Muscle rupture	0	1 (0.6)	0
Muscle strain	0	1 (0.6)	0
Peripheral artery restenosis	0	0	1 (0.4)
Post procedural complication	0	0	1 (0.4)
Post procedural hematoma	0	1 (0.6)	0
Post-traumatic pain	0	2 (1.1)	0
Postoperative renal failure	0	1 (0.6)	0
Procedural dizziness	0	1 (0.6)	0
Scapula fracture	0	0	1 (0.4)
Skin wound	0	0	1 (0.4)
Spinal fracture	0	1 (0.6)	0
Tibia fracture	0	0	1 (0.4)

Supplementary Table SII. Cont.

Primary System Organ Class Preferred term, n (%) of patients	High-intensity statin (n = 580)	Low/moderate-inten- sity statin (n = 181)	No statin (n = 233)
Surgical and medical procedures:	2 (0.3)	1 (0.6)	0
Dermabrasion	1 (0.2)	0	0
Meniscus removal	1 (0.2)	0	0
Large intestinal polypectomy	0	1 (0.6)	0
Social circumstances:	2 (0.3)	1 (0.6)	2 (0.9)
Pregnancy of partner	1 (0.2)	1 (0.6)	1 (0.4)
Stress at work	1 (0.2)	0	0
Menopause	0	0	1 (0.4)
Product issues:	0	0	1 (0.4)
Device dislocation	0	0	1 (0.4)

*High-intensity statin was defined as atorvastatin 40 or 80 mg, rosuvastatin 20 or 40 mg, or simvastatin 80 mg daily; low/moderate-intensity statin was defined as all other statins and/or doses.

Supplementary Table SIII. Overview of TEAEs according to prior ezetimibe medication (safety population)

Parameter	Prior ezetimibe (n = 556)	No ezetimibe (n = 438)
Overview:		
Any TEAE	378 (68.0)	334 (76.3)
Treatment-emergent SAEs	72 (12.9)	89 (20.3)
TEAEs leading to death	1 (0.2)	1 (0.2)
TEAEs leading to permanent treatment discontinuation	19 (3.4)	26 (5.9)
TEAEs listed by system organ class and preferred term:		
Infections and infestations:	161 (29.0)	142 (32.4)
Nasopharyngitis	40 (7.2)	38 (8.7)
Influenza	26 (4.7)	27 (6.2)
Bronchitis	24 (4.3)	21 (4.8)
Urinary tract infection	6 (2.9)	11 (2.5)
Gastroenteritis	13 (2.3)	7 (1.6)
Rhinitis	13 (2.3)	7 (1.6)
Sinusitis	10 (1.8)	7 (1.6)
Cystitis	8 (1.4)	4 (0.9)
Upper respiratory tract infection	7 (1.3)	4 (0.9)
Pharyngitis	6 (1.1)	4 (0.9)
Tonsillitis	5 (0.9)	3 (0.7)
Tooth abscess	5 (0.9)	2 (0.5)
Viral infection	4 (0.7)	3 (0.7)
Laryngitis	3 (0.5)	1 (0.2)
Oral herpes	3 (0.5)	3 (0.7)
Conjunctivitis	2 (0.4)	0
Diverticulitis	2 (0.4)	2 (0.5)
Ear infection	2 (0.4)	0
Herpes virus infection	2 (0.4)	0
Herpes zoster	2 (0.4)	2 (0.5)
Oral candidiasis	2 (0.4)	1 (0.2)
Pneumonia	2 (0.4)	6 (1.4)
Tooth infection	2 (0.4)	2 (0.5)
Tracheitis	2 (0.4)	2 (0.5)
Viral pharyngitis	2 (0.4)	0
Appendicitis	1 (0.2)	0
Bronchitis viral	1 (0.2)	0
Carbuncle	1 (0.2)	0
Cellulitis	1 (0.2)	2 (0.5)
Dysentery	1 (0.2)	0
Escherichia sepsis	1 (0.2)	0
Fungal skin infection	1 (0.2)	0
Gastroenteritis viral	1 (0.2)	3 (0.7)
Gastrointestinal fungal infection	1 (0.2)	0
Genital herpes	1 (0.2)	0
Genital infection female	1 (0.2)	0
Helicobacter gastritis	1 (0.2)	0
Helicobacter infection	1 (0.2)	1 (0.2)
Helminthic infection	1 (0.2)	0

Supplementary Table SIII. Cont.

Parameter	Prior ezetimibe (n = 556)	No ezetimibe (n = 438)
Otitis media	1 (0.2)	1 (0.2)
Parotitis	1 (0.2)	0
Periodontitis	1 (0.2)	1 (0.2)
Pharyngitis bacterial	1 (0.2)	0
Pharyngotonsillitis	1 (0.2)	0
Rash pustular	1 (0.2)	0
Respiratory tract infection	1 (0.2)	4 (0.9)
Urinary tract infection bacterial	1 (0.2)	0
Urosepsis	1 (0.2)	0
Varicella	1 (0.2)	0
Vestibular neuronitis	1 (0.2)	0
Vulvovaginal candidiasis	1 (0.2)	0
Campylobacter colitis	0	1 (0.2)
Diabetic foot infection	0	1 (0.2)
Erysipelas	0	1 (0.2)
Gastrointestinal infection	0	1 (0.2)
Gingivitis	0	2 (0.5)
Hordeolum	0	1 (0.2)
Liver abscess	0	1 (0.2)
Lower respiratory tract infection	0	1 (0.2)
Mononucleosis syndrome	0	1 (0.2)
Nail bed infection	0	1 (0.2)
Onychomycosis	0	2 (0.5)
Oral fungal infection	0	1 (0.2)
Pleurisy viral	0	1 (0.2)
Pyelonephritis	0	1 (0.2)
Respiratory tract infection bacterial	0	2 (0.5)
Tonsillitis bacterial	0	1 (0.2)
Toxoplasmosis	0	1 (0.2)
Tracheobronchitis	0	1 (0.2)
Viral sinusitis	0	1 (0.2)
Viral tonsillitis	0	1 (0.2)
Wound infection	0	1 (0.2)
Neoplasms benign, malignant, and unspecified (incl cysts and polyps):	8 (1.4)	12 (2.7)
Prostate cancer	2 (0.4)	1 (0.2)
Benign neoplasm of prostate	1 (0.2)	0
Clear cell renal cell carcinoma	1 (0.2)	0
Lentigo maligna	1 (0.2)	0
Myelodysplastic syndrome	1 (0.2)	0
Pleomorphic adenoma	1 (0.2)	0
Skin papilloma	1 (0.2)	0
Transitional cell carcinoma	1 (0.2)	0
Bladder cancer stage 0, with cancer in situ	0	1 (0.2)
Breast cancer	0	1 (0.2)
Colon adenoma	0	1 (0.2)
Gastrointestinal tract adenoma	0	1 (0.2)

Supplementary Table SIII. Cont.

Parameter	Prior ezetimibe (n = 556)	No ezetimibe (n = 438)
Lipoma	0	2 (0.5)
Lung adenocarcinoma	0	2 (0.5)
Prostatic adenoma	0	1 (0.2)
Rectal adenocarcinoma	0	1 (0.2)
Tendon neoplasm	0	1 (0.2)
Uterine cancer	0	1 (0.2)
Blood and lymphatic system disorders:	14 (2.5)	9 (2.1)
Anemia	7 (1.3)	4 (0.9)
Neutropenia	3 (0.5)	4 (0.9)
Thrombocytopenia	3 (0.5)	1 (0.2)
Hypochromic anemia	1 (0.2)	0
Idiopathic neutropenia	1 (0.2)	0
Leukopenia	0	1 (0.2)
Lymphadenopathy	0	1 (0.2)
Immune system disorders:	6 (1.1)	3 (0.7)
Allergy to arthropod sting	2 (0.4)	1 (0.2)
Seasonal allergy	2 (0.4)	0
Allergy to arthropod bite	1 (0.2)	0
Hypersensitivity	1 (0.2)	1 (0.2)
Drug hypersensitivity	0	1 (0.2)
Endocrine disorders:	4 (0.7)	4 (0.9)
Hypothyroidism	2 (0.4)	2 (0.5)
Hyperadrenalism	1 (0.2)	0
Hyperthyroidism	1 (0.2)	0
Goitre	0	1 (0.2)
Hyperparathyroidism	0	1 (0.2)
Metabolism and nutrition disorders:	26 (4.7)	34 (7.8)
Diabetes mellitus	7 (1.3)	4 (0.9)
Type 2 diabetes mellitus	4 (0.7)	2 (0.5)
Decreased appetite	3 (0.5)	4 (0.9)
Hyperglycemia	2 (0.4)	3 (0.7)
Hypoglycemia	2 (0.4)	0
Dehydration	1 (0.2)	0
Diabetes mellitus inadequate control	1 (0.2)	5 (1.1)
Fluid retention	1 (0.2)	0
Gout	1 (0.2)	5 (1.1)
Hyperkalemia	1 (0.2)	2 (0.5)
Hypertriglyceridemia	1 (0.2)	2 (0.5)
Hyperuricemia	1 (0.2)	3 (0.7)
Hypocalcemia	1 (0.2)	0
Hypokalemia	1 (0.2)	0
Hypomagnesaemia	1 (0.2)	0
Impaired fasting glucose	1 (0.2)	0
Increased appetite	1 (0.2)	0
Glucose tolerance impaired	0	3 (0.7)
Hyponatremia	0	1 (0.2)

Supplementary Table SIII. Cont.

Parameter	Prior ezetimibe (n = 556)	No ezetimibe (n = 438)
Metabolic syndrome	0	1 (0.2)
Vitamin B12 deficiency	0	1 (0.2)
Vitamin D deficiency	0	2 (0.5)
Psychiatric disorders:	26 (4.7)	20 (4.6)
Insomnia	9 (1.6)	4 (0.9)
Depression	7 (1.3)	1 (0.2)
Anxiety	4 (0.7)	5 (1.1)
Anxiety disorder	1 (0.2)	1 (0.2)
Completed suicide	1 (0.2)	0
Confusional state	1 (0.2)	2 (0.5)
Disorganized speech	1 (0.2)	0
Irritability	1 (0.2)	0
Mental disorder	1 (0.2)	0
Middle insomnia	1 (0.2)	0
Psychological trauma	1 (0.2)	0
Sleep disorder	1 (0.2)	1 (0.2)
Stress	1 (0.2)	1 (0.2)
Suicide attempt	1 (0.2)	0
Apathy	0	1 (0.2)
Depressive symptom	0	1 (0.2)
Hallucination	0	1 (0.2)
Libido decreased	0	1 (0.2)
Schizophrenia	0	1 (0.2)
Nervous system disorders:	70 (12.6)	78 (17.8)
Headache	26 (4.7)	36 (8.2)
Dizziness	12 (2.2)	6 (1.4)
Sciatica	7 (1.3)	3 (0.7)
Syncope	4 (0.7)	3 (0.7)
Dysgeusia	3 (0.5)	0
Amnesia	2 (0.4)	1 (0.2)
Balance disorder	2 (0.4)	0
Carotid artery stenosis	2 (0.4)	4 (0.9)
Hypoesthesia	2 (0.4)	3 (0.7)
Migraine	2 (0.4)	2 (0.5)
Paresthesia	2 (0.4)	(0.9)
Carpal tunnel syndrome	1 (0.2)	3 (0.7)
Cerebrovascular accident	1 (0.2)	0
Cluster headache	1 (0.2)	0
Complex regional pain syndrome	1 (0.2)	0
Dizziness postural	1 (0.2)	0
Intention tremor	1 (0.2)	0
Ischemic cerebral infarction	1 (0.2)	0
Lethargy	1 (0.2)	0
Memory impairment	1 (0.2)	1 (0.2)
Neuropathy peripheral	1 (0.2)	2 (0.5)
Perineurial cyst	1 (0.2)	0

Supplementary Table SIII. Cont.

Parameter	Prior ezetimibe (n = 556)	No ezetimibe (n = 438)
Presyncope	1 (0.2)	6 (1.4)
Seizure	1 (0.2)	0
Tension headache	1 (0.2)	0
Transient ischemic attack	1 (0.2)	2 (0.5)
Ataxia	0	1 (0.2)
Burning sensation	0	2 (0.5)
Cervicobrachial syndrome	0	1 (0.2)
Diabetic neuropathy	0	1 (0.2)
Disturbance in attention	0	2 (0.5)
Facial neuralgia	0	1 (0.2)
Facial paralysis	0	1 (0.2)
Head discomfort	0	1 (0.2)
Hypokinesia	0	1 (0.2)
Ischemic stroke	0	1 (0.2)
Nerve compression	0	1 (0.2)
Neuralgia	0	1 (0.2)
Peripheral sensorimotor neuropathy	0	1 (0.2)
Restless legs syndrome	0	1 (0.2)
Thoracic outlet syndrome	0	1 (0.2)
Visual field defect	0	1 (0.2)
Eye disorders:	26 (4.7)	19 (4.3)
Cataract	5 (0.9)	3 (0.7)
Dry eye	3 (0.5)	1 (0.2)
Blepharitis	2 (0.4)	0
Conjunctival hemorrhage	2 (0.4)	0
Eye pain	2 (0.4)	1 (0.2)
Arcus lipoides	1 (0.2)	0
Conjunctival hyperemia	1 (0.2)	0
Conjunctivitis allergic	1 (0.2)	1 (0.2)
Dacryostenosis acquired	1 (0.2)	0
Eye inflammation	1 (0.2)	0
Eye pruritus	1 (0.2)	1 (0.2)
Maculopathy	1 (0.2)	0
Retinal hemorrhage	1 (0.2)	0
Retinal tear	1 (0.2)	0
Swelling of eyelid	1 (0.2)	0
Visual acuity reduced	1 (0.2)	0
Visual impairment	1 (0.2)	1 (0.2)
Vitreous detachment	1 (0.2)	0
Amaurosis fugax	0	1 (0.2)
Diplopia	0	1 (0.2)
Eye allergy	0	1 (0.2)
Eye irritation	0	1 (0.2)
Eyelid ptosis	0	1 (0.2)
Halo vision	0	1 (0.2)
Lacrimation increased	0	1 (0.2)

Supplementary Table SIII. Cont.

Parameter	Prior ezetimibe (n = 556)	No ezetimibe (n = 438)
Ocular hyperemia	0	1 (0.2)
Scleritis	0	1 (0.2)
Vision blurred	0	3 (0.7)
Ear and labyrinth disorders:	12 (2.2)	14 (3.2)
Vertigo	4 (0.7)	8 (1.8)
Ear pain	2 (0.4)	0
Vertigo positional	2 (0.4)	3 (0.7)
Ear discomfort	1 (0.2)	1 (0.2)
Excessive cerumen production	1 (0.2)	0
Otosclerosis	1 (0.2)	0
Tinnitus	1 (0.2)	1 (0.2)
Meniere's disease	0	1 (0.2)
Cardiac disorders:	55 (9.9)	52 (11.9)
Angina pectoris	15 (2.7)	19 (4.3)
Angina unstable	8 (1.4)	5 (1.1)
Coronary artery stenosis	7 (1.3)	2 (0.5)
Myocardial ischemia	5 (0.9)	2 (0.5)
Palpitations	5 (0.9)	3 (0.7)
Acute coronary syndrome	4 (0.7)	1 (0.2)
Acute myocardial infarction	4 (0.7)	1 (0.2)
Coronary artery disease	4 (0.7)	4 (0.9)
Atrial fibrillation	3 (0.5)	5 (1.1)
Cardiac failure	3 (0.5)	4 (0.9)
Atrioventricular block second degree	2 (0.4)	1 (0.2)
Pericarditis	2 (0.4)	0
Aortic valve stenosis	1 (0.2)	0
Arrhythmia	1 (0.2)	0
Arteriosclerosis coronary artery	1 (0.2)	0
Atrial tachycardia	1 (0.2)	0
Myocardial infarction	1 (0.2)	2 (0.5)
Tachycardia	1 (0.2)	1 (0.2)
Atrial flutter	0	1 (0.2)
Bradycardia	0	3 (0.7)
Cardiac failure chronic	0	1 (0.2)
Cardiac failure congestive	0	1 (0.2)
Coronary ostial stenosis	0	1 (0.2)
Mitral valve stenosis	0	1 (0.2)
Subendocardial ischemia	0	1 (0.2)
Ventricular extrasystoles	0	2 (0.5)
Ventricular fibrillation	0	1 (0.2)
Vascular disorders:	42 (7.6)	48 (11.0)
Hypertension	15 (2.7)	25 (5.7)
Hypotension	6 (1.1)	8 (1.8)
Hematoma	3 (0.5)	2 (0.5)
Aortic aneurysm	2 (0.4)	0
Intermittent claudication	2 (0.4)	0

Supplementary Table SIII. Cont.

Parameter	Prior ezetimibe (n = 556)	No ezetimibe (n = 438)
Peripheral arterial occlusive disease	2 (0.4)	3 (0.7)
Aortic dilatation	1 (0.2)	0
Aortic stenosis	1 (0.2)	0
Arteritis	1 (0.2)	0
Circulatory collapse	1 (0.2)	0
Deep vein thrombosis	1 (0.2)	1 (0.2)
Hemorrhage	1 (0.2)	0
Hot flush	1 (0.2)	3 (0.7)
Hypertensive crisis	1 (0.2)	1 (0.2)
Peripheral artery aneurysm	1 (0.2)	0
Peripheral artery stenosis	1 (0.2)	3 (0.7)
Peripheral coldness	1 (0.2)	0
Thrombophlebitis	1 (0.2)	1 (0.2)
Varicose vein	1 (0.2)	0
Aortic dissection	0	1 (0.2)
Flushing	0	1 (0.2)
Peripheral artery thrombosis	0	1 (0.2)
Respiratory, thoracic, and mediastinal disorders:	43 (7.7)	46 (10.5)
Cough	11 (2.0)	6 (1.4)
Dyspnea	11 (2.0)	6 (1.4)
Rhinitis allergic	5 (0.9)	2 (0.5)
Asthma	3 (0.5)	1 (0.2)
Chronic obstructive pulmonary disease	2 (0.4)	1 (0.2)
Sleep apnea syndrome	2 (0.4)	2 (0.5)
Allergic cough	1 (0.2)	0
Dry throat	1 (0.2)	1 (0.2)
Dysphonia	1 (0.2)	1 (0.2)
Dyspnea exertional	1 (0.2)	5 (1.1)
Epistaxis	1 (0.2)	8 (1.8)
Laryngeal edema	1 (0.2)	0
Lung disorder	1 (0.2)	1 (0.2)
Oropharyngeal pain	1 (0.2)	8 (1.8)
Productive cough	1 (0.2)	0
Pulmonary mass	1 (0.2)	0
Rhinorrhea	1 (0.2)	2 (0.5)
Sneezing	1 (0.2)	1 (0.2)
Snoring	1 (0.2)	0
Allergic bronchitis	0	1 (0.2)
Asthmatic crisis	0	1 (0.2)
Bronchiectasis	0	1 (0.2)
Bronchitis chronic	0	1 (0.2)
Choking sensation	0	1 (0.2)
Emphysema	0	1 (0.2)
Hemoptysis	0	1 (0.2)
Nasal obstruction	0	1 (0.2)
Nasal pruritus	0	1 (0.2)
Pulmonary embolism	0	1 (0.2)

Supplementary Table SIII. Cont.

Parameter	Prior ezetimibe (n = 556)	No ezetimibe (n = 438)
Gastrointestinal disorders:	82 (14.7)	90 (20.5)
Diarrhea	27 (4.9)	18 (4.1)
Nausea	11 (2.0)	11 (2.5)
Abdominal pain	10 (1.8)	5 (1.1)
Abdominal pain upper	5 (0.9)	11 (2.5)
Constipation	5 (0.9)	14 (3.2)
Gastroesophageal reflux disease	5 (0.9)	3 (0.7)
Dry mouth	3 (0.5)	3 (0.7)
Flatulence	3 (0.5)	3 (0.7)
Gastritis	3 (0.5)	1 (0.2)
Hemorrhoids	3 (0.5)	2 (0.5)
Toothache	3 (0.5)	0
Dyspepsia	2 (0.4)	5 (1.1)
Hemorrhoidal hemorrhage	2 (0.4)	2 (0.5)
Inguinal hernia	2 (0.4)	3 (0.7)
Mouth ulceration	2 (0.4)	0
Vomiting	2 (0.4)	7 (1.6)
Abdominal distension	1 (0.2)	2 (0.5)
Abdominal rigidity	1 (0.2)	0
Abdominal wall hematoma	1 (0.2)	1 (0.2)
Anal fissure	1 (0.2)	0
Anorectal discomfort	1 (0.2)	0
Aphthous ulcer	1 (0.2)	0
Breath odor	1 (0.2)	0
Colitis	1 (0.2)	2 (0.5)
Colitis ischemic	1 (0.2)	0
Diverticulum intestinal	1 (0.2)	1 (0.2)
Enterocolitis hemorrhagic	1 (0.2)	0
Feces soft	1 (0.2)	0
Food poisoning	1 (0.2)	1 (0.2)
Intra-abdominal hematoma	1 (0.2)	0
Lower gastrointestinal hemorrhage	1 (0.2)	0
Noninfective gingivitis	1 (0.2)	0
Esophagitis	1 (0.2)	1 (0.2)
Oral discomfort	1 (0.2)	0
Oral mucosal eruption	1 (0.2)	1 (0.2)
Oral pruritus	1 (0.2)	0
Pigmentation lip	1 (0.2)	0
Rectal hemorrhage	1 (0.2)	1 (0.2)
Salivary hypersecretion	1 (0.2)	0
Stomatitis	1 (0.2)	2 (0.5)
Tongue dry	1 (0.2)	0
Umbilical hernia	1 (0.2)	1 (0.2)
Abdominal discomfort	0	2 (0.5)
Anal pruritus	0	1 (0.2)
Chronic gastritis	0	1 (0.2)

Supplementary Table SIII. Cont.

Parameter	Prior ezetimibe (n = 556)	No ezetimibe (n = 438)
Coeliac artery compression syndrome	0	1 (0.2)
Dental caries	0	1 (0.2)
Dental cyst	0	1 (0.2)
Dental necrosis	0	1 (0.2)
Diverticular perforation	0	1 (0.2)
Diverticulum	0	2 (0.5)
Duodenitis	0	1 (0.2)
Duodenogastric reflux	0	1 (0.2)
Enteritis	0	1 (0.2)
Eructation	0	2 (0.5)
Feces pale	0	1 (0.2)
Fistula of small intestine	0	1 (0.2)
Gastric disorder	0	1 (0.2)
Gastrointestinal disorder	0	3 (0.7)
Hematemesis	0	1 (0.2)
Hemorrhoids thrombosed	0	1 (0.2)
Hernial eventration	0	1 (0.2)
Hiatus hernia	0	1 (0.2)
Hypoesthesia oral	0	1 (0.2)
Irritable bowel syndrome	0	3 (0.7)
Large intestine polyp	0	1 (0.2)
Melaena	0	1 (0.2)
Oral lichen planus	0	1 (0.2)
Palatal disorder	0	1 (0.2)
Palatal edema	0	1 (0.2)
Perianal erythema	0	1 (0.2)
Proctalgia	0	1 (0.2)
Tooth loss	0	1 (0.2)
Hepatobiliary disorders:	6 (1.1)	9 (2.1)
Hepatic steatosis	2 (0.4)	3 (0.7)
Cholelithiasis	1 (0.2)	1 (0.2)
Hepatic mass	1 (0.2)	0
Hepatocellular injury	1 (0.2)	2 (0.5)
Hepatomegaly	1 (0.2)	0
Bile duct stone	0	1 (0.2)
Cholestasis	0	1 (0.2)
Chronic hepatitis	0	1 (0.2)
Hypertransaminasemia	0	1 (0.2)
Skin and subcutaneous tissue disorders:	49 (8.8)	47 (10.7)
Pruritus	6 (1.1)	11 (2.5)
Rash	6 (1.1)	6 (1.4)
Erythema	5 (0.9)	7 (1.6)
Alopecia	4 (0.7)	0
Dry skin	4 (0.7)	1 (0.2)
Eczema	3 (0.5)	3 (0.7)
Urticaria	3 (0.5)	2 (0.5)

Supplementary Table SIII. Cont.

Parameter	Prior ezetimibe (n = 556)	No ezetimibe (n = 438)
Ecchymosis	2 (0.4)	2 (0.5)
Pruritus generalized	2 (0.4)	3 (0.7)
Dermal cyst	1 (0.2)	0
Dermatitis	1 (0.2)	0
Dermatitis allergic	1 (0.2)	1 (0.2)
Dermatitis contact	1 (0.2)	0
Drug eruption	1 (0.2)	0
Generalized erythema	1 (0.2)	0
Hyperhidrosis	1 (0.2)	0
Nail discomfort	1 (0.2)	0
Peau d'orange	1 (0.2)	0
Petechiae	1 (0.2)	0
Rosacea	1 (0.2)	1 (0.2)
Scar pain	1 (0.2)	0
Skin irritation	1 (0.2)	0
Skin lesion	1 (0.2)	0
Skin mass	1 (0.2)	1 (0.2)
Skin Plaque	1 (0.2)	0
Swelling face	1 (0.2)	1 (0.2)
Actinic keratosis	0	1 (0.2)
Fracture blisters	0	1 (0.2)
Hyperkeratosis	0	1 (0.2)
Night sweats	0	1 (0.2)
Parapsoriasis	0	1 (0.2)
Pigmentation disorder	0	1 (0.2)
Purpura	0	1 (0.2)
Rash pruritic	0	1 (0.2)
Skin burning sensation	0	1 (0.2)
Skin hyperpigmentation	0	1 (0.2)
Skin reaction	0	1 (0.2)
Xanthoma	0	2 (0.5)
Musculoskeletal and connective tissue disorders:	105 (18.9)	133 (30.4)
Myalgia	31 (5.6)	40 (9.1)
Back pain	23 (4.1)	19 (4.3)
Arthralgia	17 (3.1)	19 (4.3)
Muscle spasms	15 (2.7)	19 (4.3)
Pain in extremity	11 (2.0)	28 (6.4)
Musculoskeletal pain	10 (1.8)	4 (0.9)
Tendonitis	6 (1.1)	7 (1.6)
Arthritis	3 (0.5)	1 (0.2)
Intervertebral disc protrusion	3 (0.5)	3 (0.7)
Neck pain	3 (0.5)	5 (1.1)
Osteoarthritis	2 (0.4)	8 (1.8)
Bursa calcification	1 (0.2)	0
Exostosis	1 (0.2)	0
Fibromyalgia	1 (0.2)	1 (0.2)

Supplementary Table SIII. Cont.

Parameter	Prior ezetimibe (n = 556)	No ezetimibe (n = 438)
Gouty arthritis	1 (0.2)	4 (0.9)
Hemarthrosis	1 (0.2)	0
Joint effusion	1 (0.2)	0
Joint lock	1 (0.2)	0
Joint noise	1 (0.2)	0
Joint range of motion decreased	1 (0.2)	0
Muscle twitching	1 (0.2)	0
Muscular weakness	1 (0.2)	3 (0.7)
Musculoskeletal stiffness	1 (0.2)	2 (0.5)
Myopathy	1 (0.2)	0
Myositis	1 (0.2)	2 (0.5)
Nuchal rigidity	1 (0.2)	0
Osteoporosis	1 (0.2)	0
Plantar fasciitis	1 (0.2)	1 (0.2)
Polymyalgia rheumatica	1 (0.2)	1 (0.2)
Rheumatic disorder	1 (0.2)	2 (0.5)
Rotator cuff syndrome	1 (0.2)	2 (0.5)
Spinal osteoarthritis	1 (0.2)	3 (0.7)
Spinal pain	1 (0.2)	1 (0.2)
Spondylolisthesis	1 (0.2)	0
Synovial cyst	1 (0.2)	1 (0.2)
Ankylosing spondylitis	0	1 (0.2)
Bone pain	0	2 (0.5)
Flank pain	0	1 (0.2)
Intervertebral disc disorder	0	1 (0.2)
Joint stiffness	0	1 (0.2)
Ligamentum flavum hypertrophy	0	1 (0.2)
Limb discomfort	0	1 (0.2)
Muscle tightness	0	1 (0.2)
Musculoskeletal chest pain	0	2 (0.5)
Musculoskeletal discomfort	0	2 (0.5)
Myopathy toxic	0	1 (0.2)
Osteochondrosis	0	1 (0.2)
Osteopenia	0	1 (0.2)
Pain in jaw	0	1 (0.2)
Rheumatoid arthritis	0	1 (0.2)
Spinal column stenosis	0	1 (0.2)
Tendon disorder	0	1 (0.2)
Tendon pain	0	4 (0.9)
Tenosynovitis stenosans	0	1 (0.2)
Renal and urinary disorders:	12 (2.2)	11 (2.5)
Renal colic	3 (0.5)	2 (0.5)
Dysuria	2 (0.4)	3 (0.7)
Renal impairment	2 (0.4)	0
Diabetic nephropathy	1 (0.2)	0
Hematuria	1 (0.2)	2 (0.5)

Supplementary Table SIII. Cont.

Parameter	Prior ezetimibe (n = 556)	No ezetimibe (n = 438)
Nephrolithiasis	1 (0.2)	0
Nocturia	1 (0.2)	0
Renal disorder	1 (0.2)	0
Urinary retention	1 (0.2)	0
Acute kidney injury	0	1 (0.2)
Bladder trabeculation	0	1 (0.2)
Cystitis noninfective	0	1 (0.2)
Pyelocaliectasis	0	1 (0.2)
Pregnancy, puerperium, and perinatal conditions:	0	1 (0.2)
Pregnancy	0	1 (0.2)
Reproductive system and breast disorders:	9 (1.6)	15 (3.4)
Prostatitis	2 (0.4)	4 (0.9)
Uterine polyp	2 (0.4)	0
Benign prostatic hyperplasia	1 (0.2)	1 (0.2)
Dysmenorrhea	1 (0.2)	0
Endometrial hypertrophy	1 (0.2)	0
Fibrocystic breast disease	1 (0.2)	0
Metrorrhagia	1 (0.2)	1 (0.2)
Testicular swelling	1 (0.2)	0
Breast calcifications	0	1 (0.2)
Breast pain	0	1 (0.2)
Erectile dysfunction	0	4 (0.9)
Pelvic pain	0	1 (0.2)
Scrotal pain	0	1 (0.2)
Testicular pain	0	1 (0.2)
Vulvar dysplasia	0	1 (0.2)
Congenital, familial, and genetic disorders:	1 (0.2)	2 (0.5)
Congenital cystic kidney disease	1 (0.2)	0
Accessory navicular syndrome	0	1 (0.2)
Glycogen storage disease type V	0	1 (0.2)
General disorders and administration-site conditions:	137 (24.6)	137 (31.3)
Injection-site hematoma	25 (4.5)	18 (4.1)
Injection-site reaction	25 (4.5)	24 (5.5)
Injection-site swelling	18 (3.2)	13 (3.0)
Injection-site erythema	16 (2.9)	22 (5.0)
Asthenia	14 (2.5)	25 (5.7)
Fatigue	13 (2.3)	16 (3.7)
Injection-site pain	11 (2.0)	15 (3.4)
Influenza-like illness	8 (1.4)	6 (1.4)
Injection-site hemorrhage	8 (1.4)	9 (2.1)
Non-cardiac chest pain	8 (1.4)	17 (3.9)
Pyrexia	8 (1.4)	4 (0.9)
Injection-site bruising	6 (1.1)	8 (1.8)
Edema peripheral	6 (1.1)	4 (0.9)
Injection-site pruritus	5 (0.9)	8 (1.8)
Injection-site induration	4 (0.7)	2 (0.5)

Supplementary Table SIII. Cont.

Parameter	Prior ezetimibe (n = 556)	No ezetimibe (n = 438)
Pain	4 (0.7)	1 (0.2)
Vascular stent stenosis	3 (0.5)	1 (0.2)
Chest pain	2 (0.4)	4 (0.9)
Cyst	2 (0.4)	0
Injection-site hypersensitivity	2 (0.4)	2 (0.5)
Peripheral swelling	2 (0.4)	1 (0.2)
Adverse drug reaction	1 (0.2)	0
Chest discomfort	1 (0.2)	2 (0.5)
Chills	1 (0.2)	2 (0.5)
Drug intolerance	1 (0.2)	1 (0.2)
Feeling cold	1 (0.2)	1 (0.2)
Hyperthermia	1 (0.2)	0
Inflammation	1 (0.2)	0
Injection-site discoloration	1 (0.2)	0
Injection-site irritation	1 (0.2)	1 (0.2)
Injection-site mass	1 (0.2)	1 (0.2)
Injection-site papule	1 (0.2)	0
Injection-site urticaria	1 (0.2)	1 (0.2)
Puncture-site reaction	1 (0.2)	0
Swelling	1 (0.2)	1 (0.2)
Adverse reaction	0	1 (0.2)
Application-site hemorrhage	0	1 (0.2)
Discomfort	0	3 (0.7)
Face edema	0	1 (0.2)
Hyperpyrexia	0	2 (0.5)
Infusion-site erythema	0	1 (0.2)
Injection-site edema	0	2 (0.5)
Injection-site paresthesia	0	1 (0.2)
Injection-site warmth	0	2 (0.5)
Malaise	0	1 (0.2)
Puncture-site edema	0	1 (0.2)
Thirst	0	1 (0.2)
Vessel puncture-site hematoma	0	1 (0.2)
Investigations:	40 (7.2)	43 (9.8)
Blood creatine phosphokinase increased	10 (1.8)	10 (2.3)
Alanine aminotransferase increased	7 (1.3)	4 (0.9)
Transaminases increased	5 (0.9)	2 (0.5)
Blood pressure increased	4 (0.7)	4 (0.9)
Low density lipoprotein decreased	4 (0.7)	3 (0.7)
Aspartate aminotransferase increased	2 (0.4)	2 (0.5)
Blood glucose increased	2 (0.4)	4 (0.9)
Gamma-glutamyltransferase increased	2 (0.4)	3 (0.7)
Heart rate increased	2 (0.4)	0
Arterial bruit	1 (0.2)	0
Blood bilirubin increased	1 (0.2)	2 (0.5)
Blood creatinine increased	1 (0.2)	1 (0.2)

Supplementary Table SIII. Cont.

Parameter	Prior ezetimibe (n = 556)	No ezetimibe (n = 438)
Blood pressure systolic increased	1 (0.2)	0
Blood urea increased	1 (0.2)	0
Blood uric acid increased	1 (0.2)	1 (0.2)
Breath sounds abnormal	1 (0.2)	0
Cardiac murmur	1 (0.2)	0
Eosinophil count increased	1 (0.2)	0
Glycosylated hemoglobin increased	1 (0.2)	2 (0.5)
Low-density lipoprotein increased	1 (0.2)	0
Platelet count decreased	1 (0.2)	1 (0.2)
Platelet count increased	1 (0.2)	0
White blood cells urine positive	1 (0.2)	0
Blood glucose abnormal	0	2 (0.5)
Blood lactate dehydrogenase increased	0	1 (0.2)
Blood pressure abnormal	0	1 (0.2)
Blood triglycerides abnormal	0	1 (0.2)
Blood triglycerides increased	0	1 (0.2)
Cardiac stress test abnormal	0	2 (0.5)
Gamma-glutamyltransferase abnormal	0	1 (0.2)
Hemoglobin decreased	0	2 (0.5)
International normalized ratio increased	0	1 (0.2)
Muscle enzyme increased	0	1 (0.2)
Red blood cell count decreased	0	1 (0.2)
Waist circumference increased	0	1 (0.2)
Weight decreased	0	2 (0.5)
Weight increased	0	2 (0.5)
White blood cell count increased	0	1 (0.2)
Injury, poisoning, and procedural complications:	48 (8.6)	42 (9.6)
Fall	9 (1.6)	4 (0.9)
Contusion	5 (0.9)	1 (0.2)
Ligament sprain	4 (0.7)	3 (0.7)
Tendon rupture	3 (0.5)	4 (0.9)
Ankle fracture	2 (0.4)	1 (0.2)
Arthropod bite	2 (0.4)	1 (0.2)
Hand fracture	2 (0.4)	1 (0.2)
Joint dislocation	2 (0.4)	1 (0.2)
Joint injury	2 (0.4)	1 (0.2)
Lower limb fracture	2 (0.4)	0
Post-traumatic pain	2 (0.4)	0
Radius fracture	2 (0.4)	1 (0.2)
Upper limb fracture	2 (0.4)	3 (0.7)
Accidental overdose	1 (0.2)	4 (0.9)
Animal bite	1 (0.2)	0
Dental restoration failure	1 (0.2)	0
Electric shock	1 (0.2)	0
Face injury	1 (0.2)	0
Foot fracture	1 (0.2)	0

Supplementary Table SIII. Cont.

Parameter	Prior ezetimibe (n = 556)	No ezetimibe (n = 438)
Hip fracture	1 (0.2)	0
Kidney contusion	1 (0.2)	0
Lumbar vertebral fracture	1 (0.2)	0
Meniscus injury	1 (0.2)	2 (0.5)
Muscle injury	1 (0.2)	0
Muscle strain	1 (0.2)	0
Post procedural complication	1 (0.2)	0
Rib fracture	1 (0.2)	2 (0.5)
Scapula fracture	1 (0.2)	0
Spinal column injury	1 (0.2)	0
Spinal fracture	1 (0.2)	0
Subcutaneous hematoma	1 (0.2)	0
Sunburn	1 (0.2)	2 (0.5)
Tooth fracture	1 (0.2)	0
Vascular pseudoaneurysm	1 (0.2)	0
Wrist fracture	1 (0.2)	1 (0.2)
Arthropod sting	0	1 (0.2)
Bone fissure	0	1 (0.2)
Epicondylitis	0	1 (0.2)
Eye injury	0	1 (0.2)
Facial bones fracture	0	1 (0.2)
Gingival injury	0	1 (0.2)
Humerus fracture	0	1 (0.2)
Injury	0	1 (0.2)
Intentional overdose	0	1 (0.2)
Limb injury	0	3 (0.7)
Muscle rupture	0	1 (0.2)
Peripheral artery restenosis	0	1 (0.2)
Post procedural hematoma	0	1 (0.2)
Postoperative renal failure	0	1 (0.2)
Procedural dizziness	0	1 (0.2)
Procedural headache	0	2 (0.5)
Procedural nausea	0	3 (0.7)
Skin wound	0	1 (0.2)
Tibia fracture	0	1 (0.2)
Vascular graft occlusion	0	1 (0.2)
Surgical and medical procedures:	1 (0.2)	2 (0.5)
Meniscus removal	1 (0.2)	0
Dermabrasion	0	1 (0.2)
Large intestinal polypectomy	0	1 (0.2)
Social circumstances:	2 (0.4)	3 (0.7)
Pregnancy of partner	1 (0.2)	2 (0.5)
Stress at work	1 (0.2)	0
Menopause	0	1 (0.2)
PRODUCT ISSUES	0	1 (0.2)
Device dislocation	0	1 (0.2)

SAE – serious adverse event, TEAE – treatment-emergent adverse event.